Dexcom Inc

Dexcom’s recent institutional buying surge shows growing confidence in its CGM dominance and strong growth prospects—learn how new capital inflows could signal a short‑term rally.

Dexcom Inc. (DXCM) tops the CGM market with growing sales of G6 and G7 systems, strong 52‑week range, and a “Buy” rating – a smart long‑term health‑tech investment.

Dexcom faces class‑action suits over alleged misstatements, but analysts lift its target to $78 while investors weigh joining lawsuits and market shifts.

Explore how DexCom’s latest securities‑fraud class action and mixed analyst ratings shape investor decisions and potential stock recovery.

Dexcom’s Q3 revenue beat sparks a sharp stock slump as analysts downgrade the company and a securities fraud lawsuit threatens its growth prospects, leaving investors questioning the high P/E valuation and future upside.

Dexcom Inc.’s stock price target of $100 has been maintained by TD Cowen ahead of the company’s Q3 earnings, citing confidence in its recent product advancements and market positioning.

Dexcom Inc. has experienced significant growth and innovation over the past decade, with its continuous glucose monitoring systems becoming a leading solution for individuals with diabetes, resulting in substantial returns for investors and position…

Dexcom Inc.’s stock price has experienced a rollercoaster ride, despite beating earnings expectations and raising its revenue guidance, due to market volatility and leadership changes.

Dexcom Inc. has seen a surge in stock value and strategic advancements, solidifying its position as a leader in the healthcare technology sector with innovative continuous glucose monitoring systems.

Dexcom Inc.’s stock surged on May 2, 2025, despite a first-quarter earnings miss, driven by strong revenue growth and strategic announcements, including a new product launch and share repurchase program.